AI-Powered Precision Therapeutics for Acute Illness
Our mission is to tailor healthcare to each patient’s biology by developing and delivering precision therapeutics, so each person receives the treatment they deserve.
Devastating Conditions. No Targeted Treatments.
Every patient reacts differently to acute illness like sepsis, pneumonia, and ARDS. Why? Because every patient is biologically different. Treatments that help one patient can harm another.
We spend 10 times more on acute conditions than we do on oncology. Yet there have been no novel therapeutics in this space in decades, leaving the largest unmet need in healthcare, and representing a massive market opportunity.
Prenosis is the only company that is aligning AI, technology, and biology to develop precision therapeutics.
Spend Per Year Worldwide
Why Treatments Have Failed
Solving Patient Heterogeneity.
Patients with the same clinical diagnosis can have very different underlying biology and very different responses to treatment.
Conventional clinical trials and treatment protocols often fail to account for this heterogeneity, obscuring the patients who may benefit.
Using AI-powered deep biological profiling, Prenosis makes those differences visible and actionable.
The Platform Behind the Mission
AI-Powered.
Biology-Driven.
EHR-Integrated.
Our proprietary, EHR-integrated software connects one of the largest acute-illness biobanks in existence to a continuously growing multimodal dataset, using powerful AI models to identify which patients are most likely to respond to which treatment, and deliver that insight to clinicians in real time.
Our platform continuously maps the biology behind immune-driving disease – turning that insight into a growing pipeline of precision therapeutics – making it more precise with every patient treated.
End-to-End Infrastructure
Enabling a New Class of Precision Therapeutics
The solution? Prenosis is building the infrastructure through which precision therapeutics are discovered, developed, validated, and delivered
The data that makes targeted treatment possible
Prenosis has built one of the largest acute-illness biobanks in existence: more than 140,000 longitudinal biospecimens from more than 35,000 patients, growing through a network of leading clinical research sites. AI translates that biology into insight about which treatment will work for which patient.
From signal to precision therapeutics
AI-Biomarkers integrate multiple types of data to show which patients will respond to which treatments. We apply them to mature drug candidates, redefining patient populations and improving the odds of late-stage success.
The clinical network that proves what works
We’ve reimagined clinical trial methodology for critical illness. Our biology-first clinical trial infrastructure simultaneously generates data, reveals new therapeutic-response populations, validates therapeutics, and identifies appropriate patients for targeted treatment in real-time.
The software that uses AI to surface biological insights
Our Immunix® platform is the engine that identifies, clinically validates, and delivers precision therapeutics. Its first commercial application, Sepsis ImmunoScore®, is the first-ever FDA-authorized AI diagnostic for sepsis, and the first step in an expanding pipeline of precision therapeutics.
In The News
Stay Updated on the Latest Media and News Coverage
August 31, 2026
Prenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq Bell
August 27, 2026
Precision Medicine Transformed Oncology — It’s Time to Do the Same for Sepsis
July 28, 2026